Spotlight

The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma

• W I Bensinger

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

• A J Barrett
• B N Savani

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL

• F X E Gruber
• T Lamark
• B Skogen

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

• S Colla
• F Morandi
• N Giuliani

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

• L C Crossman
• T O'Hare
• M W N Deininger

Enhanced growth suppression of Philadephia¹ leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy

• X L Cong
• B Li
• Z C Han

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

• K-H Lee
• J-H Lee
• H-S Chi

Antiangiogenic treatment with endostatin inhibits progression of AML in vivo

• G Schuch
• L Oliveira-Ferrer
• S Ergun

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

• A Takeshita
• K Shinjo
• R Ohno

Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis

• T Sanda
• T Kuwano
• R Ueda

Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications

• P Korkolopoulou
• I Thymara
• G A Pangalis

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

• D Marin
• J Kaeda
• J F Apperley

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

• Y K Lee
• T D Shanafelt
• N E Kay

VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli

• L Wang
• L Chen
• L F Gibson

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells

• M Farahani
• A T Treweeke
• H Chen

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)

• R L Levine
• M Wadleigh
• J Cools

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

• K Cwynarski
• R Laylor
• F Dazzi

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia

• C Terre
• V Eclache
• M Lessard

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

• T Illmer
• M Schaich
• E Schleyer

Imatinib sensitizes CLL lymphocytes to chlorambucil

• R Aloyz
• K Grzywacz
• L Panasci